Literature DB >> 17001295

Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

Claudia Toscano1, Kathrin Klein, Julia Blievernicht, Elke Schaeffeler, Tanja Saussele, Sebastian Raimundo, Michel Eichelbaum, Matthias Schwab, Ulrich M Zanger.   

Abstract

We investigated the molecular basis for low expression and activity of CYP2D6 associated with the CYP2D6*41 allele in about 10-15% of Caucasians with intermediate metabolizer phenotype. With respect to two previously described polymorphisms in the promoter (-1584C>G) and in intron 6 (2988G>A; c.985+39G>A), the three most frequent functional alleles have the distinct haplotypes 2D6*1[CG], 2D6*2[GG] and 2D6*41[CA], respectively. Reporter gene analyses in transiently transfected HepG2 and Huh7 hepatoma cells did not indicate changes in transcription rate by these polymorphisms. By reverse-transcription polymerase chain reaction analysis of liver RNA of genotyped patients, however, we discovered that the 2988G>A change was associated with increased levels of a nonfunctional splice variant lacking exon 6. Quantification by denaturing high-performance liquid chromatography revealed up to 7.3-fold increased levels of the splice variant and up to 2.9-fold less functional transcript in carriers of 2D6*41, in good concordance with concomitant changes in immunoquantified CYP2D6 protein. Recombinant expression of the entire genomic sequence coding for 2D6*41, 2D6*2 and 2D6*1 alleles but lacking the upstream region in COS-1 and Huh7 cell lines resulted in two-fold to five-fold reduced levels of CYP2D6 mRNA containing exon 6, apoprotein and enzyme activity of 2D6*41. These experiments establish the causal relationship between the intron 6 single-nucleotide polymorphism 2988G>A and the low expression phenotype associated with allele 2D6*41. These data improve the CYP2D6 genotype-phenotype relationship and they demonstrate that major phenotype changes occurring in large population subgroups can be caused by intronic polymorphisms outside of splice site consensus sequences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001295     DOI: 10.1097/01.fpc.0000230112.96086.e0

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  28 in total

1.  Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.

Authors:  Victoria M Pratt; Barbara Zehnbauer; Jean Amos Wilson; Ruth Baak; Nikolina Babic; Maria Bettinotti; Arlene Buller; Ken Butz; Matthew Campbell; Chris Civalier; Abdalla El-Badry; Daniel H Farkas; Elaine Lyon; Saptarshi Mandal; Jason McKinney; Kasinathan Muralidharan; LeAnne Noll; Tara Sander; Junaid Shabbeer; Chingying Smith; Milhan Telatar; Lorraine Toji; Anand Vairavan; Carlos Vance; Karen E Weck; Alan H B Wu; Kiang-Teck J Yeo; Markus Zeller; Lisa Kalman
Journal:  J Mol Diagn       Date:  2010-10-01       Impact factor: 5.568

Review 2.  Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.

Authors:  W Sadee; D Wang; A C Papp; J K Pinsonneault; R M Smith; R A Moyer; A D Johnson
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

3.  Drug therapy and personalized health care: pharmacogenomics in perspective.

Authors:  Wolfgang Sadee
Journal:  Pharm Res       Date:  2008-08-26       Impact factor: 4.200

4.  Toxicogenetics--cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam.

Authors:  H Andresen; C Augustin; T Streichert
Journal:  Int J Legal Med       Date:  2012-08-17       Impact factor: 2.686

5.  Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World.

Authors:  Ahmed Elzawawy
Journal:  Breast Care (Basel)       Date:  2008-11-25       Impact factor: 2.860

6.  Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual.

Authors:  Andrea Gaedigk; Dorothee Frank; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-09-17       Impact factor: 2.953

7.  Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms.

Authors:  Ke-Da Yu; Zhi-Ming Shao
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

8.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

Authors:  Sam Mostafa; Carl M J Kirkpatrick; Keith Byron; Leslie Sheffield
Journal:  J Neural Transm (Vienna)       Date:  2018-09-06       Impact factor: 3.575

9.  Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.

Authors:  Tore Haslemo; Erik Eliasson; Marin M Jukić; Magnus Ingelman-Sundberg; Espen Molden
Journal:  Br J Clin Pharmacol       Date:  2018-11-11       Impact factor: 4.335

Review 10.  Cytochrome P450 2D6.

Authors:  Ryan P Owen; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.